EIF4A1 and cancer: The antineoplastic activity of eFT226, an inhibitor of the translation initiation factor eIF4A1, has been reported in a variety of cancer cells [25], eFT226 recently became the first rocaglate to enter clinical evaluation for advanced solid tumors in humans (ClinicalTrials.gov: NCT04092673) [23].